Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    UnavailableHealthcare: 3 Genomics Stocks Revolutionizing Healthcare And Why Alnylam's New Deal Didn't Excite Investors
    Currently unavailable

    Healthcare: 3 Genomics Stocks Revolutionizing Healthcare And Why Alnylam's New Deal Didn't Excite Investors

    FromIndustry Focus

    View podcast show
    Currently unavailable

    Healthcare: 3 Genomics Stocks Revolutionizing Healthcare And Why Alnylam's New Deal Didn't Excite Investors

    FromIndustry Focus

    ratings:
    Length:
    32 minutes
    Released:
    Apr 10, 2019
    Format:
    Podcast episode

    Description

    Here's why a $1 billion deal with Regeneron failed to spark a rally in Alnylam shares. Also, will genetic discovery be our generation's biggest trend? If so, Illumina, bluebird bio, and Invitae could be top stocks to watch. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter
    Released:
    Apr 10, 2019
    Format:
    Podcast episode

    Titles in the series (100)

    Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.